Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Well 2
2023-504238-23-00Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2023
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in hepatitis B (HBV) comparing Bepirovirsen arm with Placebo arm (2 arms). Primary endpoint: Functional cure at 24 weeks after discontinuation of all chronic HBV treatment. Started Jan 2023; status: completed.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2023-504238-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504238-23-00.